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Summarn Renal allograft recipients suffer from a markedly increased susceptibility to premalignant and
malignant cutaneous lesions. Although various aetiological factors have been implicated. little is known of the
associated genetic events. In this study we initially employed immunocytochemical techniques to investigate the
prevalence and localisation of accumulated p53 in over 200 cutaneous biopsies (including 56 squamous cell
carcinomas) from renal allograft recipients and immunocompetent controls. In renal allograft recipients
accumulated p53 was present in 24% of uninvolved skin samples. 14% of viral warts. 41% of premalignant
keratoses. 65% of intraepidermal carcinomas and 56% of squamous cell carcinomas [squamous cell carcinoma
and intraepidermal carcinoma differed significantly from uninvolved skin (P<0.005) and viral warts
(P<0.01)1. A similar trend was revealed in immunocompetent patients (an older, chronically sun-exposed
population) but with lower prevalence of p53 immunoreactivity: 25% of uninvolved skin samples. 0%0 of viral
warts. 25% of keratoses. 53% of intraepidermal carcinomas and 53% of squamous cell carcinomas. These
differences were not statistically significant. Morphologically. p53 immunoreactivity strongly associated with
areas of epidermal dysplasia and the abundance of staining correlated positively with the severity of dysplasia.
These data suggest that p53 plays a role in skin carcinogenesis and is associated with progression towards the
invasive state. No correlation was observed between accumulated p53 and the presence of human papil-
lomavirus (HPV) DNA in any of the lesions. Single-strand conformational polymorphism analysis (exons 5-8)
was used to determine the frequency of mutated p53 in 28 malignancies with varying degrees of
immunopositivity. p53 mutations were found in 5 9 (56%) malignancies with p53 staining in > 50%0 of cells.
reducing to 1 6 (17%) where 10-50% of cells were positively stained and none where <10% of cells were
stained. These data imply that factors other than p53 gene mutation play a part in accumulation of p53 in skin
cancers.
The p53 gene encodes a 53 kDa phosphoprotein that acts as
a transcription factor and has tumour-suppressor functions.
The wild-type gene product also has the ability to induce
growth arrest and or apoptosis in response to DNA injury.
preventing replication of genomes that have suffered DNA
damage (Kastan et al.. 1991: Hartwell, 1992: Lane. 1992.
1993; Unger et al.. 1992: Clark et al.. 1993; Hall et al., 1993).
Mutations in the p53 gene are considered to play a significant
part in the development of many human malignancies: a high
frequency of mutation is observed in most of the common
forms of human cancer and there are elevated rates of malig-
nancy in patients with Li-Fraumeni syndrome (in which
there is an inherited p53 gene mutation) and in genetically
engineered, p53-deficient mice (Baker et al., 1989; Nigro et
al.. 1989; Srivastava et al.. 1990; Hollstein et al.. 1991:
Donehower et al.. 1992; Purdie et al.. 1994). A number of
oncogenic viral proteins can also form complexes with wild-
type p53. initiating gene inactivation by mechanisms other
than mutational loss of function (Scheffner et al., 1990; Yew
& Berk. 1992; Debbas & White. 1993: Moran. 1993). Most of
the mutations observed in p53 are thought to induce confor-
mational changes in the protein product. increasing its half-
life and rendering it detectable by immunocytochemical
techniques (Milner & Cook. 1986; Gannon et al., 1990;
Milner & Medcalf. 1991: Montenarh. 1992: Wynford-
Thomas. 1992).
Renal allograft recipients (RARs) manifest a greatly in-
creased susceptibility to cutaneous malignancy, with squam-
ous cell carcinoma (SCC) occurring commonly, especially in
patients with long graft life or high sun exposure (Shuttle-
worth et al., 1987: Alloub et al.. 1989; Benton et al., 1992).
These malignancies, however, form part of the wider spect-
rum of cutaneous disease observed in RARs that includes
viral warts (VWs) and keratoses (Ks) displaying varying
degrees of epidermal dysplasia and topographical continuity
with intraepidermal carcinoma (IEC) and invasive SCC (Bles-
sing et al., 1989: Benton et al.. 1992). Although a number of
putative aetiological factors have been implicated in the
development of these malignancies, including ultraviolet
(UV) radiation (Blohme & Larko, 1984; Boyle et al.. 1984),
decreased cell-mediated immunity (Streilein, 1991) and
human papillomavirus (HPV) infection (Rudlinger et al.,
1986; Barr et al., 1989: Benton et al.. 1992; Stark et al..
1994), little is known of the associated genetic events and
whether these may differ in RARs and immunocompetent
patients (ICPs). To our knowledge. there have been no major
studies in which the role of p53 in the development of
cutaneous lesions in RARs has been considered, although
p53 mutations have been reported to occur in IECs and
SCCs from ICPs (Brash et al.. 1991; Gusterson et al.. 1991;
Pierceall et al., 1991; McGregor et al.. 1992: Burns et al.,
1993; Campbell et al., 1993a, b).
In this study we have employed immunocytochemical tech-
niques to compare the prevalence of p53 accumulation in
premalignant and malignant cutaneous lesions from both
RARs and ICPs. Single-strand conformational polymor-
phism (SSCP) analysis was also employed to determine the
relationship between positive immunocytochemistry and p53
gene mutations. The relationship between p53 expression and
the HPV satus of the lesions was also considered since it has
been reported that viral oncoproteins may play a part in p53
inactivation in other HPV-associated malignancies (Scheffner
et al., 1990, 1991, 1992; Werness et al.. 1990; Crook et al..
1991, 1992).
Materials and methods
Patients
Sixty RARs (mean age 49 years, range 20-71 years) and 83
ICPs (mean age 68 years, range 12-94 years) were investi-
gated. All SCCs came from 10 RARs and 17 ICPs. RARs
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received transplants between 1965 and 1992 (mean duration
of transplant 10.8 years, range 1-26 years). Prior to 1984,
prednisolone and azathiopnrne were the main immunosup-
pressive drugs used, but thereafter most patients received
prednisolone and cyclosporin A. ICPs all presented to the
Dermatology Department in Edinburgh Royal Infirmary for
treatment of viral warts or skin tumours. Most of these
patients were elderly with lesions on sun-exposed sites.
Tissue collection
One hundred and thirty-five and 68 cutaneous lesions were
collected from RARs and ICPs respectively. These included
56 SCCs and 62 IECs. Six millimetre punch biopsies of
normal (sun-exposed), forearm skin were also collected from
21 RARs and 12 ICPs. Biopsy samples were bisected longi-
tudinally; half were placed immediately in PLPD (periodate-
lysine-paraformaldehyde-dichromate) (Holgate et al., 1986),
or 10% formalin and fixed for 24 h at 4'C before paraffin
embedding. Histological assessment and immunohistochemi-
stry were carried out on sections prepared from paraffin-
embedded material. The other half were snap frozen in liquid
nitrogen and stored at - 70°C to await DNA extraction and
virological investigation.
DNA extraction and HPV detection
Frozen tissue was minced in lysis buffer (50 mM Tris, 50 mM
EDTA, 100 mM sodium chloride, 5 mM DTT, 1% SDS
1.5 mg ml-1 proteinase K) then incubated at 3TC overnight.
DNA extraction was carried out using a standard
phenol-chloroform extraction technique (Sambrook et al..
1989). Two methods were employed to screen for the pre-
sence of HPV DNA (Stark et al., 1994). Southern analysis,
using mixed HPV probes at low hybridisation (Tm -40°C)
and washing stringency (Tm - 35C), was used to detect com-
mon cutaneous and epidermodysplasia verruciformis (EV)-
related types. The polymerase chain reaction (PCR) was used
to detect specific HPV types 1, 2, 5, 8, 6, 11. 16 and 18
(Arends et al., 1991; Stark et al., 1994).
Histopathologv
The skin lesions were classified as follows: viral warts (VWs)
exhibited symmetry, papilliferous architecture and koilocytic
change; verrucous keratoses (VKs) displayed the architecture
of warts but lacked definitive cytological features of viral
infection; actinic keratoses (AKs) showed basal budding and
basal hypermelanosis (degrees of dysplasia were assessed in
both types of keratosis); intraepidermal carcinoma (IECs)
showed either full-thickness dysplasia or severe dysplasia and
acantholysis of the basal layer, invasive squamous cell car-
cinoma (SCC) showed dermal invasion (Blessing et al., 1989).
Immunocitochemistry
Immunocytochemistry was performed on 3 fLm sections of
PLPD- and formalin-fixed tissue using the mouse anti-p53
monoclonal antibodies MAb Do-7 (Vojtesek et al., 1992) and
PAb 1801 (Banks et al., 1986) and a standard ABC horse-
radish peroxidase (HRP) technique (Dako, High Wycombe,
Bucks, UK) as previously described (Purdie et al., 1991).
Formalin-fixed tissue was treated with MAb Do-7 (1:100
dilution, overnight incubation) only, whereas PLPD-fixed
material was treated with MAb Do-7 and PAb 1801 (1:100
dilution. 1 h incubation). Each section was scored by two
independent observers and the extent of staining recorded on
the following graded scale: 1 = <10%, 2 = 10-50% and
3 = > 50% of cells in a lesion showing positive nuclear stain-
ing. Sections were recorded as positive when immune pre-
cipitate was visible in > 10% of cells in the lesion, i.e. grades
2 and 3 only. Lesions with grade 1 score were considered to
be negative. The histological localisation of accumulated p53
within each lesion was also noted.
Single-strand conformational polv morphism (SSCP) analysis
and direct DNA sequencing
Twenty-eight tumour samples and 12 normal skin samples
from RARs and ICPs underwent SSCP analysis. PCR was
performed on 0.1-1 .jg of genomic DNA using primers
specific for p53 exons 5. 6, 7 and 8. SSCP analysis was based
on the protocol of Cripps et al. (manuscript in preparation).
The 100 tlI PCR reaction was purified using a standard
chloroform extraction technique. A 5-10 ILI volume of the
purified product was alkali denatured (80 ALM sodium hydrox-
ide, 10 .LM EDTA. at 48°C for 5 min). 10 1I of stop solution
added (10mM EDTA, 0.1% bromophenol blue, 0.01%
xylene cyanol) and the whole sample loaded onto a 5%
glycerol, 0.5 x MDE Hydrolink gel. Following electro-
phoresis (25°C. 20 W, for 2-3 h) the DNA was visualised by
silver staining (BioRad kit). SSCP mutations were detected as
bands of altered mobility. In one sample showing an exon 7
mutation by SSCP analysis, sequencing was performed using
the Sequenase (II) kit (United States Biochemical) with
cloned double-stranded DNA.
Results
Immunocvtochemical demonstration ofp53
Experiments were initially carried out to determine the
specificity and sensitivity of MAb Do-7 and PAb 1801 stain-
ing in PLPD- and formalin-fixed material. No statistically
significant difference in the number of positive cases was
detected in formalin- or PLPD-fixed material (data not
shown). permitting results from both fixatives to be com-
bined. In 74 lesions tested with both MAb Do-7 and PAb
1801 the number of positive cases was identical, and within
each section both antibodies reacted with similarly located
cells. Overall, MAb Do-7 gave a more intense precipitate
than PAb 1801. although some minor variation in intenstiy
occurred between assays.
Accumulatedp53 in cutaneous lesionsfrom RARs and ICPs
A total of 156 biopsies from RARs and 80 from ICPs were
screened for the presence of accumulated p53 using MAb
Do-7 (Table I, Figures I and 2). In both populations, over
50% of SCCs exhibited p53 immunoreactivity in > 10% of
cells (grades 2 and 3). Overall, the number of lesions
exhibiting accumulated p53 and the grade of staining within
these lesions correlated positively with the degree of dysplasia
present. In RARs, significantly more IECs and SCCs demon-
strated accumulated p53 than either uninvolved sun-exposed
skin (US) (X: test, P<0.05) or VWs (X: test. P<0.01). A
similar trend was revealed in ICPs, although a lower propor-
tion of cases were stained positive for p53. However, the
differences between SCCs or IECs and US in ICP were not
statistically significant.
Distribution ofaccumulatedp53
In both RARs and ICPs, immunostaining of lesions was
confined to nuclei of dysplastic epithelial cells and was most
Table I Prevalence of accumulated p53 in cutaneous lesions from
RAR and ICPs
No. oflesions (%0) demonstrating accumulatedpS53
Patients U'S VWUs Ks IECs SCCs
RARs 5 21 (24)b 3 21 (14)' 17 41 (41) 22 34 (65)bc 22 39 (56)b-c
ICPs 3 12 (25) 0 7 (0) 4 16 (25) 15 28 (53) 9 17 (53)
"Sections with staining in >IO%o ofnuclei in the lesion (grades 2 and
3) were scored as positive. RAR. renal allograft recipient; ICP.
immunocompetent patient; VW. viral wart: K. verrucous and actinic
keratosis; IEC. intraepidermal carcinoma: SCC. squamous cell car-
cinoma: US. uninvolved. sun-exposed skin. bp<0.05 using y test.
,PP<0.0l using r test.664 L.A. STARK et al.
abundant in areas of severe dysplasia (Figure 2a). Within K
and IEC lesions. staining was generally strongest in basal
epithelial layers, particularly at sites of basal budding where
dysplastic changes were most severe (Figure 2a and b). This
was particularly notable in Ks exhibiting actinic features. In
dysplastic Ks and IECs, acantholysis and suprabasal clefting
were also observed to correlate with strong p53 staining. In
tissue sections that contained skin appendages, the specialised
lining cells were always negative and staining was confined to
the surrounding dysplastic cells (Figure 2c). While the
majority of SCCs showed accumulated p53, there was a
tendency for greater positivity to occur in less well-
differentiated lesions (Figure 2d) and adjacent normal epider-
mis remained unstained. Occasionally, p53 was detected in
dysplastic basal cells and overlying IECs but not in con-
tiguous tongues of invasive carcinoma. The positive staining
in non-lesional. sun-exposed skin was light in intensity and
ICP Histology RAR
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. ~~~vw us.
K
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80 60 40 20 0 0 20 40 60 80
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Fige 1 Extent of p53 staining in cutaneous lesions from RARs
and ICPs. Grade I ( )=<10I. of cells, grade 2 ( M)=
10-50% of cells. grade 3 (-)=>50% of cells in a lesion
showing positive nuclear staining by immunocytochemistry; neg
( [ ) = negative by immunocytochemistry. US, uninvolved, sun-
exposed skin; VW. viral wart; K, keratosis; IEC. intraepidermal
carcinoma. SCC. squamous cell carcinoma.
predominantly basal in location in cells exhibiting only mild
dysplastic change.
HPV status andpresence ofaccumulatedp53
One hundred and twenty-six biopsies from RARs and 75
from ICPs were also screened for the presence of HPV DNA
using low-stringency Southern hybnrdisation with a cocktail
of HPV probes, and type-specific PCR for HPV types 1, 2. 5,
8. 6. 11, 16 and 18 (Table II). The details of these results are
reported elsewhere (Stark et al.. 1994). Overall, no relation-
ship was observed between the presence of accumulated p53
and HPV DNA in premalignant or malignant cutaneous
lesions from RARs or ICPs. The prevalences of the specific
HPV types 1. 2. 5. 8. 6. 11. 16 and 18 were also too low to
determine whether any correlation existed between these
HPV types and p53 immunoreactivity.
SSCP analysis ofp53 immunopositive and immunonegative
lesions
SSCP analysis of exons 5-8 of the p53 gene was performed
on 28 IECs/'SCCs from RARs and ICPs. Fifteen of these
were immunopositive (grades 2 and 3) and 13 were immuno-
negative (including seven with grade 1 staining) (Table III
and Figure 3). Overall, SSCP mutations (SSCPs) were
detected in 6/28 (21%) malignancies [3,15 (20%) SCCs and
3 13 (23%) IECs]. However, the incidence of mutation was
related to the grade of p53 positivity detected by immuno-
cytochemistry with 5/9 (56%) grade 3. 1 /6 (17%) grade 2 and
no grade I lesions showing SSCPs. Three of the SSCPs were
in exon 7 (all grade 3), two in exon 5 (one grade 3, the other
grade 2) and one in exon 8 (grade 3). In our series, no SSCPs
were detected in immunonegative cancers or matched normal
skin samples and there was no difference in the number of
SSCPs present in RARs and ICPs. Direct DNA sequencing
of one SCC with a SSCP mutation in exon 7 revealed a C-T
transition at codon 248 (Figure 3). SSCPs were detected in
Figure 2 Histological distribution of accumulated p53. a, Severely dysplastic keratosis (left) is associated with strong p53
immunostaining as compared with negative normal epidermis (right). b, p53 immunostaining is localised to the dysplastic basal cells
in actinic keratosis. c. Dysplastic basal cells are positive for p53 while the specialised cells in appendages are negative. d. Nuclear
localisation of p53 in an invasive squamous cell carcinoma from a RAR. p53 immunocytochemistry was performed using PAb
Do-7 and a standard ABC horseradish peroxidase technique.p53 AND SKIN CARCINOGENESIS IN RAR 665
Table11 Correlation between presenceofHPV DNAandaccumulated
p53 in cutaneous lesions from RARs and ICPs
RARs ICPs
HPV+ HPV- HPV+ HPV-
Histology p53+ p53s- p53+ p53- p53+ a p53 p53+a p53
US 0 3 3 3 5 16 11 16 11 01 2 11 9 11
VWs I 10 910 05 55 15 45 11 01
Ks 4 10 6 10 6 19 13 19 0 3 3 3 3 11 8 11
IECs 8 12 4 12 13 20 7 20 2 4 2 4 13 24 11 24
SCCs 7 15 8 15 10 16 6 16 3 5 25 4 10 6 10
aSections with staining in >10% ofnuclei in the lesion (grade 2and 3)
were scored as positive. RAR. renal allograft recipient: ICP.
immunocompetent patient: US. uninvolved, sun-exposed skin. VW.
viral wart. K. keratosis; IEC. intraepidermal carcinoma: SCC.
squamous cell carcinoma
Table III SSCP analysis of immunopositive and immunonegative
tumours from RARs and ICPs
No. ofICCpositive and negative lesions
exhibiting SSCPs
Patients Histology- Neg Grade I Grade 2 Grade 3
RARs SCC 0 1 0 3 0 2 3 3
IEC 03 0 1 0 1 1 2
Normal 0 5 0 2 - -
ICPs SCC - 0 2 0 2 0 2
IEC 02 0 1 1 1 12
Normal 0 5
ICC. immunocytochemical; SSCPs. p53 mutations as detected by
SSCP analysis: grade 1. <10O. grade 2. 10-50o; grade 3. 5 S0% of
cells in a lesion showing positive nuclear staining: RAR. renal allograft
recipient: ICP. immunocompentent patient. SCC, squamous cell car-
cinoma: IEC. intraepidermal carcinoma.
three HPV-positive malignancies and one HPV-negative
malignancy.
p53 accumulation andprogression in cutaneous carcinogenesis
In this study we have demonstrated the presence of accumu-
lated p53 in over 50% of cutaneous SCCs from both RARs
and ICPs suggesting that p53 may play a role in skin car-
cinogenesis in both populations. This detection level is in
broad agreement with previously reported results for SCC in
ICPs in which it has ranged from 15% to 56% of lesions
(Gusterson et al., 1991; McGregor et al., 1992; Ro et al..
1992). A striking feature of our study was the increase in
prevalence and extent of staining which occurred as lesions
progressed through the histological spectrum of neoplasia.
Indeed, there was a close correlation between the extent of
staining in these lesions and the severity of dysplasia. These
results strongly suggest that in skin carcinogenesis, in both
RARs and ICPs, accumulation of p53 represents an impor-
tant step in malignant progression. This hypothesis is sup-
ported by recent studies of skin carcinogenesis in p53 null
mice, in which inactivation of p53 specifically associates with
progression of benign papillomas to SCCs (Kemp et al.,
1993). It is important to note, however, that the occurrence
of p53 immunoreactivity does not always equate with ac-
quisition of the malignant state since in ICPs accumulated
p53 can be demonstrated in solar keratoses, of which only a
small proportion progress to invasive carcinoma (Marks et
al., 1986). Clearly, other genetic events must contribute to the
development of invasive skin malignancies. In this context it
is also of interest that we found a small number of SCCs
showing p53 staining in superficial dysplastic epidermis and
adjacent areas of IEC but not in contiguous tongues of
invasive SCC. One possible explanation for this may be that
gross chromosomal deletions, involving 17p, have occurred in
more invasive malignant elements, abolishing all p53 gene
expression.
Exon 5
AI 1i
a Exon 5
Wt 36
6-
Exon 7
1 wt
b Sample 1
G C A T
Fige 3 a. Examples of SSCP mutations in exons 5 and 7 of
p53 in cutaneous malignancies from RARs and ICPs. Using
SSCP analysis, a single base change, such as a point mutation, is
visualised as a band of altered migration (as indicated by arrows)
in a polyacrylamide gel. Samples 1 and 16 = squamous cell
carcinomas from renal allograft recipients, both with grade 3
staining by immunocytochemistry (ICC): sample 36 = an intra-
epidermal carcinoma from an immunocompetent patient with
grade 2 staining by ICC. b. Direct DNA sequencing of exon 7
from sample I showing a C-T transition at codon 248 of
p53.
HPV andp53 in cutaneous lesionsfrom RARs and ICPs
E6 oncoproteins from HPV types 16 and 18 can bind to and
induce rapid degradation of wild-type p53 (Scheffner et al.,
1990; Werness et al., 1990). From observations in anogenital
cancers it has been proposed that p53 inactivation occurs
either by complexing of wild-type p53 with such viral onco-
proteins or, in the absence of virus, by mutational loss of
gene function (Crook et al., 1991, 1992; Scheffner et al., 1991.
1992). This concept, however, remains controversial, and
other workers have failed to confirm these suggestions
(Busby-Earle et al., 1993; Cooper et al., 1993). We have
recently reported the prevalence of HPV in cutaneous lesions
from RARs (Stark et al., 1994) and suggested that the
mechanism by which HPV contributes to skin carcinogenesis
may differ from that proposed for anogenital cancer. The
present study confirms our previous findings in that we have
failed to demonstrate any relationship between the presence
or absence of HPV DNA and accumulated p53 in dysplastic
or frankly malignant skin lesions from RARs or ICPs.
Moreover, p53 mutations were detected by SSCP analysis in
both HPV-positive and -negative malignancies. Recently, it
has also been demonstrated that the E6 oncoprotein from
skin-associated HPV type 8 does not bind to p53, unlike its
HPV 16 or 18 equivalent (Steger & Pfister, 1992). Therefore,
if HPV is involved in cutaneous carcinogenesis, it must be
presumed to act by a different mechanism from that found in
anogenital cancer.
p53 mutations in cutaneous carcinogenesis
In this study SSCP analysis was used to demonstrate muta-
tions in the p53 gene. Although the precise sensitivity of this
technique is presently unknown, a recent study in our
laboratory involving human colorectal cancer, in which both
SSCP analysis and direct sequencing were performed. indi-666 L.A. STARK et al.
cates that approximately 80% of p53 mutations can be de-
tected by SSCP analysis (Cripps et al., manuscript in
preparation). The detection of p53 mutations in 21% of
SCCsJIECs in our series is in agreement with previous
reports for cutaneous cancer (Pierceall et al., 1991; Ro et al..
1992; Campbell et al., 1993a, b). With one exception, these
mutations occurred in exons 5 and 7, in keeping with the
suggestion that these exons contain mutational hotspots for
most human malignancies (Brash et al., 1991; Hollstein et al.,
1991; Pierceall et al., 1991; Campbell et al., 1993a; Levine,
1993). Molecular analysis of p53 mutations has previously
suggested that the pattern of nucleotide alterations may be
tissue dependent and related to the type of mutagenic agent
involved (Harris, 1991; Vogelstein & Kinzler, 1992). For
instance, CC to rT double-base changes are almost exclus-
ively associated with UV-induced DNA damage (Brash et al.,
1991). It is of interest, therefore, that the SCC in our series
that was sequenced was found to contain a C-T transition at
the codon 248 mutational hotspot, implicating UV radiation
in its genesis.
p53 immunocytochemical detection andgene mutations
Immunocytochemistry has been proposed as a rapid and
simple means of identification of p53 gene mutations. In the
majority of tumours. good correlation has been observed
between the presence of immunocytochemically stable p53
and gene mutations determined by sequencing or other
methods (Gannon et al., 1990; Iggo et al., 1990; Bodner et
al., 1992). However, it is also recognised that immuno-
cytochemically detectable levels of wild-type p53 may occur
in response to DNA injury, and that some p53 mutations do
not result in immunocytochemical demonstration of p53 pro-
tein (Bodner et al.. 1992; Oliner et al., 1992; Wynford-
Thomas, 1992; Hall et al.. 1993, Lane. 1993). In this study.
SSCP analysis of exons 5-8 detected mutations in 6,15
(40%) immunopositive malignancies, with most mutations
occurring in tumours with the largest number of positive cells
(grade 3 lesions). This indicates that immunocytochemical
detection of p53 does not always signify the presence of p53
gene mutations in skin cancers, particularly where there are
relatively few positive cells. While the possibility remains that
mutations may have occurred in exons other than 5-8. our
own experience and that of others studying other common
cancers suggests that this is likely to account for only a small
proportion of cases. This implies that additional factors may
contribute to the accumulation of p53 during the develop-
ment of at least some skin cancers. Recently, the product of
the mdn-2 gene, which is overexpressed in osteosarcomas,
has been shown to bind to and inactivate p53 (Momand et
al.. 1992; Oliner et al., 1992). It is possible that similar
proteins may be present in transformed epidermal cells. com-
plexing with wild-type p53 and rendering it detectable by
immunocytochemical methods. The identity of such proteins
and their role in the accumulation of p53 and subsequent
development of skin cancer remain to be established.
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